Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Jike Cui"'
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 4, Iss 8, p e782 (2010)
Trichomonas vaginalis has an unusually large genome (approximately 160 Mb) encoding approximately 60,000 proteins. With the goal of beginning to understand why some Trichomonas genes are present in so many copies, we characterized here a family of ap
Externí odkaz:
https://doaj.org/article/7c78594975fd4b13a7b98f5037567795
Autor:
Joseph Scandura, Srdan Verstovsek, Marina Kremyanskaya, Moshe Talpaz, Raajit K Rampal, Alessandro Vannucchi, Vikas Gupta, Francesca Palandri, Andrea Patriarca, Prithviraj Bose, Dong Chen, Oksana Zavidij, Jike Cui, Tzuu-Wang Chang, Pietro Taverna, John Mascarenhas, Claire Harrison
Publikováno v:
Blood. 140:1523-1525
Autor:
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Marielle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek, Natalia Curto-García, Claire Harrison, Vikas Gupta
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need. Pelabresib (CPI-0610) is an investigat
Autor:
Oksana Zavidij, Nicholas J Haradhvala, Rosana Meyer, Jike Cui, Srdan Verstovsek, Stephen Oh, Adam Mead, Pietro Taverna
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22
Abnormal differentiation of the megakaryocytic lineage and overproduction of proinflammatory cytokines, resulting in bone marrow fibrosis, anemia, symptoms, extramedullary hematopoiesis, and often hepatosplenomegaly, are key characteristics of myelof
Autor:
Oksana Zavidij, Nicholas J Haradhvala, Rosana Meyer, Jike Cui, Srdan Verstovsek, Stephen Oh, Adam Mead, Pietro Taverna
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S156
Autor:
Jing Wang, Oksana Zavidij, Srdan Verstovsek, Horatiu Olteanu, Dong Chen, Patrick Trojer, Patricia J. Keller, Claire N. Harrison, Moshe Talpaz, Katarina Luptakova, Gozde Colak, April Chiu, Mohamed E. Salama, Jike Cui, Curtis A. Hanson, Raajit Rampai, John Mascarenhas, Alessandro M. Vannucchi, Ruben A. Mesa, Zehua Chen, Stephen T. Oh, Jennifer A. Mertz, Jeffrey S. Humphrey
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S363-S364
Context: Pelabresib (CPI-0610) is a potent, selective BET bromodomain inhibitor under investigation in the ongoing Phase 2 MANIFEST trial, given as monotherapy to ruxolitinib (rux)-intolerant/refractory myelofibrosis (MF) pts in arm 1, as an “add-o
Autor:
Vikas Gupta, Suresh Bobba, John Mascarenhas, Francesca Palandri, Lino L. Teichmann, Srdan Verstovsek, Gozde Colak, Prithviraj Bose, Jike Cui, Claire N. Harrison, Mark Drummond, Witold Prejzner, Sergey Efuni, Alessandro M. Vannucchi, Ronald Hoffman, Gary J. Schiller, Marina Kremyanskaya, Andrea Patriarca, Natalia Curto-Garcia, Nikki Granacher, Joseph M. Scandura, Zheng Ren, Moshe Talpaz, Raajit K. Rampal
Publikováno v:
Blood. 138:141-141
Background: Pelabresib (CPI-0610) is a potent, first-in-class, selective, oral small-molecule inhibitor of bromodomain and extraterminal domain (BET) proteins which is able to modify the expression of genes involved in nuclear factor kappa B (NFκB)
Autor:
Patrick Trojer, Patricia J. Keller, Moshe Talpaz, April Chiu, Srdan Verstovsek, Pietro Taverna, Sergey Efuni, Claire N. Harrison, Natalia Curto-Garcia, Curtis A. Hanson, Dong Chen, Mohamed E. Salama, Raajit K. Rampal, Zehua Chen, Stephen T. Oh, John Mascarenhas, Gozde Colak, Horatiu Olteanu, Alessandro M. Vannucchi, Ruben A. Mesa, Jike Cui, Oksana Zavidij
Publikováno v:
Blood. 138:2568-2568
Background: Myelofibrosis (MF) is characterized by progressive bone marrow (BM) fibrosis resulting from aberrant megakaryopoiesis and expression of pro-inflammatory cytokines. These processes, heavily influenced by bromodomain and extraterminal domai
Autor:
Vikas Gupta, Marina Kremyanskaya, John Mascarenhas, Francesca Palandri, Andrea Patriarca, Timothy Devos, Claire Harrison, Francesco Passamonti, Raajit Rampal, Adam Mead, Joseph Scandura, Gabriela Hobbs, Moshe Talpaz, Nikki Granacher, Tim Somervaille, Ronald Hoffman, Prithviraj Bose, Gozde Colak, James Shao, Jike Cui, Suresh Bobba, Katarina Luptakova, Srdan Verstovsek
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S234
Autor:
Jike Cui, Joseph M. Scandura, James Shao, Andrea Patriarca, Gozde Colak, Prithviraj Bose, Marina Kremyanskaya, Nikki Granacher, Francesco Passamonti, Moshe Talpaz, Srdan Verstovsek, John Mascarenhas, Raajit K. Rampal, Gabriela S. Hobbs, Timothy Devos, Suresh Bobba, Francesca Palandri, Claire N. Harrison, Tim C. P. Somervaille, Vikas Gupta, Adam J. Mead, Katarina Luptakova, Ronald Hoffman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S362
Context: Pelabresib (CPI-0610), a first-in-class, oral, small-molecule inhibitor of BET proteins (BETi), has potential to promote disease-modifying activity through altered gene regulation of key oncogenic, fibrotic, and inflammatory factors in MF. T